GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Purchase Of Property, Plant, Equipment

I-MAB (IMAB) Purchase Of Property, Plant, Equipment : $-3.87 Mil (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is I-MAB Purchase Of Property, Plant, Equipment?

I-MAB's purchase of property, plant, equipment for the six months ended in Dec. 2023 was $0.00 Mil. It means I-MAB spent $0.00 Mil on purchasing property, plant, equipment. I-MAB's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.87Mil.

Compared with last quarter ($0.00 Mil in Jun. 2023 ), I-MAB spent the same money on purchasing property, plant, equipment in Dec. 2023 ($0.00 Mil).

I-MAB Purchase Of Property, Plant, Equipment Historical Data

The historical data trend for I-MAB's Purchase Of Property, Plant, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

I-MAB Purchase Of Property, Plant, Equipment Chart

I-MAB Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Purchase Of Property, Plant, Equipment
Get a 7-Day Free Trial -1.75 -1.23 -4.70 -6.57 -1.59

I-MAB Semi-Annual Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Purchase Of Property, Plant, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.06 -2.82 -3.87 - -

I-MAB Purchase Of Property, Plant, Equipment Calculation

The amount used to purchase PPE.

Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was $-3.87 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

I-MAB Purchase Of Property, Plant, Equipment Related Terms

Thank you for viewing the detailed overview of I-MAB's Purchase Of Property, Plant, Equipment provided by GuruFocus.com. Please click on the following links to see related term pages.

I-MAB (IMAB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » I-MAB (NAS:IMAB) » Definitions » Purchase Of Property, Plant, Equipment
Comparable Companies
PLX GLSI CDXS CYT SEER PROK MLEC AADI ABSI GOSS OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
0VY:Germany
Address
555 West Haiyang Road, 55th Floor, New Bund Center, Pudong District, Shanghai, CHN, 200124
Website
https://www.i-mabbiopharma.com
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.